Weight loss drugs are bringing down the country's obesity rate, a survey shows

A recent Gallup survey indicates that the widespread adoption of GLP-1 weight loss drugs is correlating with a decline in the U.S. obesity rate, which fell to 37% from 39.9% three years ago, as usage of these medications more than doubled to 12.4% of respondents. While these drugs are proving effective, particularly in the 40-64 age demographic, significant access challenges are emerging, with private insurers reportedly discontinuing coverage for many patients next year, potentially limiting broader market penetration due to high out-of-pocket costs around $500 per month, despite a concurrent rise in diabetes rates to a record 13.8%.

Analysis

The U.S. obesity rate has declined to 37% from 39.9% three years prior, a trend correlated with the rapid adoption of GLP-1 agonist medications like semaglutide and tirzepatide. Gallup's survey indicates that the proportion of respondents using these weight loss drugs more than doubled in 18 months, reaching 12.4% compared to 5.8% in February 2024. This marks a significant shift in public health metrics, suggesting a direct impact from these pharmaceutical interventions.

GLP-1s are proving effective, particularly among the 40-64 age cohort, where obesity rates dropped 5.0 points to 42.8%, aligning with higher drug usage in this demographic. While these drugs are considered a "watershed" in combating obesity, the survey also reported a record-high diabetes rate of 13.8%, indicating that the broader health crisis persists despite advancements in weight management. This suggests a complex interplay of factors beyond just obesity rates.

However, the future market penetration of GLP-1s faces significant headwinds due to access limitations. Many private insurers are reportedly discontinuing coverage for these medications next year, which could force patients to bear out-of-pocket costs of approximately $500 per month. This impending coverage reduction poses a substantial barrier to widespread adoption, potentially limiting the addressable market for drug manufacturers like Novo Nordisk and Eli Lilly despite their positive per-ticker sentiment.

Key Decisions for Investors

• Investors should closely monitor evolving insurance coverage policies for GLP-1 medications, as these will significantly impact market access and revenue projections for key players like Novo Nordisk and Eli Lilly, despite current positive efficacy data
• Evaluate the potential for drugmakers to introduce more affordable or orally administered versions, which could mitigate current access barriers and expand the addressable market
• Consider the long-term implications of sustained GLP-1 adoption on adjacent healthcare sectors, including medical devices for obesity-related conditions and diabetes management